What's Happening?
Personalis, Inc. has secured its fourth Medicare coverage decision for the NeXT Personal minimal residual disease (MRD) test, expanding its use to monitor pre-surgical treatment in breast cancer patients. The coverage now includes Stage II-III Triple-Negative
and HER2-positive breast cancer, allowing for more precise monitoring of therapy response. The decision is based on clinical evidence from the PREDICT-DNA study, which demonstrated the test's effectiveness in tracking neoadjuvant therapy response.
Why It's Important?
The expanded Medicare coverage for NeXT Personal represents a significant advancement in personalized cancer care. By enabling more precise monitoring of treatment response, the test can improve patient outcomes and guide clinical decisions. This development highlights the growing importance of personalized medicine in oncology, where tailored approaches can lead to more effective and targeted treatments. The decision also underscores the role of advanced genomic profiling in enhancing cancer management strategies.
